



Biotech Daily

Thursday December 8, 2022

Daily news on ASX-listed biotechnology companies

Actinogen Treats First Xanamem Depression Patient

[ACTINOGEN MEDICAL](#)

Actinogen says it has treated the first of 160-patients in its, randomized, controlled, phase II trial of the effects of Xanamem on patients with major depression disorder.

In June, Actinogen said it was planning a six-week, phase II, major depressive disorder proof-of-concept, placebo-controlled study of 10mg Xanamem daily or placebo, in addition to anti-depressant therapy, to test the effects on both depression and cognition, with results expected in late 2023 or 2024 (BD: Jun 14, 2022).

Today, the company said the 'Xanacidd' trial would enrol about 160 patients, rather with results expected by "late 2023, or early 2024".

Actinogen said the trial would include patients with persistent major depressive disorder and cognitive difficulties, despite a standard course of anti-depressant therapy.

Actinogen managing-director Dr Steven Gourlay said the company was "very pleased to announce the formal start of our trial in patients with major depressive disorder and cognitive impairment who are inadequately treated by their current anti-depressant medication".

"There is a strong scientific rationale for reducing brain cortisol levels to improve symptoms in depression," Dr Gourlay said.

“Xanamem has the potential to be an effective low-dose daily oral therapy for the treatment of depression, Alzheimer’s disease and many other neurological conditions ... alone or in combination with other treatments,” Dr Gourlay said.

Actinogen was unchanged at 11.5 cents with 1.9 million shares traded.